Mutations in valosin-containing protein (VCP), an ATPase involved in protein degradation and autophagy, cause VCP disease, a progressive autosomal dominant adult onset multisystem proteinopathy. The goal of this study is to examine if phenotypic differences in this disorder could be explained by the specific gene mutations. We therefore studied 231 individuals (118 males and 113 females) from 36 families carrying 15 different VCP mutations. We analyzed the correlation between the different mutations and prevalence, age of onset and severity of myopathy, Paget's disease of bone (PDB), and frontotemporal dementia (FTD), and other comorbidities.
| INTRODUCTION
Inclusion body myopathy (IBM) associated with Paget's disease of bone (PDB) and frontotemporal dementia (FTD) (IBMPFD) or multisystem proteinopathy is an adult-onset progressive, autosomal dominant ultimately lethal disease that involves degeneration of 3 main organ systems: muscle, bone, and brain. Most cases are caused by heterozygous missense mutations in valosin-containing protein (VCP). 1, 2 As awareness increases we are realizing that VCP disease is not as rare as previously considered as it is often misdiagnosed as related disorders.
| Pathology of IBMPFD
IBM is characterized by progressive weakness and atrophy of skeletal muscles of pelvic and shoulder girdle muscles. Ultimately, patients die from respiratory failure, cardiomyopathy and cardiac failure. 3 Histologically, IBM consists of cytoplasmic rimmed vacuoles containing the same proteins that aggregate in the brains of patients with neurodegenerative diseases: tau, amyloid, and TAR DNA-binding protein-43 (TDP-43). 4 PDB is a unique skeletal disease caused by overactive osteoclasts and an imbalance between osteoclast and osteoblast function. The result is a gain in bone mass, but the new bone is disorganized, weak, and prone to fractures. Typical radiological findings of PDB include coarse trabeculation, cortical thickening and spotty sclerosis. Clinical features include bone pain, bone enlargement, bowing of long bones, large head, fractures, hearing loss due to auditory foramen narrowing, and arthritis. Rare complications include kidney stones, osteosarcoma, and high-output heart failure due to the formation of arteriovenous shunts in bone. 5 FTD is an early-onset type of dementia that is typically diagnosed in younger patients roughly 60% occurring in people 45 to Ebaa Al-Obeidi and Sejad Al-Tahan contributed equally to the manuscript.
64 years old, 6 however, in VCP disease is associated with an earlier age of onset. Degeneration and atrophy of the frontal and temporal lobes of the brain results in changes in personality and progressive loss of language. Brain histology in patients with IBMPFD affected by FTD is characterized by gliosis, spongiosis, and neuronal intranuclear inclusions. 7 TDP-43 aggregates are commonly associated with VCPassociated FTD as well as in amyotrophic lateral sclerosis (ALS). 4, 8, 9 TDP-43 is a DNA/RNA-binding protein involved in various cellular processes including RNA transcription and splicing. [10] [11] [12] We have previously shown that the presence of 1 or 2 APOE4 alleles is associated with an increased risk of developing FTD in patients with VCP disease. 13 Mutations in VCP have also been associated with a spectrum of other diseases including ALS, 14 hereditary spastic paraplegia, 15 Charcot-Marie-Tooth type 2 (CMT2) disease. 16 Other common disorders that have an overlap with VCP disease include facioscapulohumeral muscular dystrophy (FSH), limb-girdle muscular dystrophy (LGMD), scapuloperoneal muscular dystrophy (SPMD), inclusion body myositis, and distal myopathy/oculopharyngeal muscular dystrophy. domains (D1 and D2), and a C-terminal region. 18 Valosin is a 25 amino acid peptide named after its N-terminal valine and C-terminal tyrosine, and was originally isolated from the porcine gut. 19 That peptide sequence is present in VCP, which is a highly abundant ATPase found in all cells where it interacts with various adaptor proteins to carry out many essential cellular processes. Among them are endoplasmic reticulum-associated degradation, 20 transcription factor processing, 21 nuclear envelope reconstruction, 22 membrane fusion, 23 post-mitotic golgi reassembly, 24 spindle disassembly, 25 and cell cycle control. 26 Several of these activities are associated with the ubiquitin-proteasome system in which VCP helps deliver ubiquitylated substrates to the 26S proteasome for degradation. 27 VCP's roles in protein degradation and autophagy is implicated in the pathogenesis of IBMPFD, and may account for the cytoplasmic inclusions observed in muscle, bone, and neuronal tissue. 1, 27 The hypothesis is that the location of the mutation may influence certain roles of VCP and thus lead to variation in the phenotype seen in VCP. 
| Molecular studies
Mutation analysis of the VCP gene (NM_007126) was carried out as previously described in CLIA-certified DNA diagnostic laboratories at the Mitomed Laboratory at UC Irvine, CA or at Prevention Diagnostic Laboratory, Marshfield, WI. 
| Statistical analysis
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Four individuals (2.1%) were diagnosed with Alzheimer's disease (AD): one had the G97E mutation (family 50), one had the R159H mutation (family 55), and one had R155H (family 3). We previously reported a case of early onset Alzheimer with 2 APOE4 alleles in family 2.
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Although VCP multisystem disorder is associated with a triad of symptoms, only 10% of the patients in our study presented with all three main features of the disorder (Figure 1) . Myopathy was the most common symptom, presenting in 89% of patients and as an isolated feature in 36%. PDB was diagnosed in 43% of patients, and in 5% it was the sole clinical feature. A total of 29% patients had FTD, and in 3% this was the sole feature.
| Genotype-phenotype studies
To elucidate the effect of different mutations on phenotypic variations, the families were divided into 15 groups according to their VCP mutation (Tables 1 and 2 ). Most mutations involved exon 5 which was mutated in 83% of individuals followed by mutations in exon 6 in 8% individuals. The frequency and mean age of onset of myopathy, PDB, and FTD, ALS, PD and AD as well as biological markers (CK and ALP) for each mutation group were compared to identify any statistically significant differences. Some of the mutation groups were too small for a statistical analysis of this sort. For IBM, mutation group R159C was found to have a later age of onset of muscle weakness (57 years) compared with L198W (37 years), R155H (43 years), R155P (43 years) or R155C (38 years) (P = <.04).
No statistically significant differences were identified for PDB or FTD. We also did not see a higher incidence of ALS or PD with any specific mutation types. The G97E mutation was reported to be associated with CMT2
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; however, we did not find any case of CMT in our cohort of patients.
| DISCUSSION
VCP disease is an autosomal dominant syndrome associated with progressive inclusion body limb-girdle type myopathy, PDB, FTD (IBMPFD), and ALS. We report genotype-phenotype studies in patients bearing 1 of the 15 mutations in this report to determine whether correlations exist between a patient's mutation and the age of onset of their symptoms and associated manifestations. The primary findings are the general lack of genotype-phenotype correlations because of the enormous phenotypic heterogeneity within and between families. We found an incidence of 90% for the myopathy, 42% for PBD, 30% for FTD, 9% for classic ALS, and 4% for PD (Table 1 ). Detailed analysis of VCP patients, however, shows motor neuron involvement is apparent in the majority of study participants.
Benatar et al. found 3 patients with unequivocal UMN findings and 4 with subtle UMN findings in a cohort of 10 patients from 6 VCP families. 36 Although the levels were in the normal range, there was large variability in the value of CK. We noted that the levels were higher among pre-symptomatic gene carriers, compared with their unaffected relatives suggesting that mild CK elevations may be early indicators of muscle pathology in some individuals. Similarly, we noted that ALP was overall much higher in the pre-symptomatic carriers without PDB than their non-carrier relatives indicating it may be a good marker for early diagnosis of PDB. Radionuclide bone scans are also sensitive in establishing the early diagnosis of PDB having identified several pre-symptomatic individuals with normal ALP levels.
Radionuclide bone scans thus offer the potential to treat patients pre-symptomatically in order to prevent PDB from progressing. Our data has also shown that VCP-associated PDB has a mean earlier onset of 41.2 years compared with PDB in the general population with an average age of onset of 50 years. 2 Similarly, VCP-associated FTD is associated with an early onset form of dementia at an average age of 55.9 years vs a typical age of onset of 65 years. mutations. In particular, the R155 locus is a mutation hotspot. Previous genotype-phenotype analysis showed that the R155C mutation was associated with an earlier age of onset of myopathy and PDB, 2 however, analysis of a larger dataset in this report did not confirm this finding. The only statistically significant difference between the mutation groups was the later age of onset of myopathy in patients with the R159C mutation compared with the R155H, R155C, R155P, and L198W mutations. This suggests that there may not be significant differences in the age of onset of symptoms among IBMPFD patients with different VCP mutations; however, some of the groups are too small for this type of analysis. We previously reported that the A232E mutation is associated with a more severe phenotype 1 in a small family. This report is supported by our data which shows the A232 mutation as having an earlier onset of PDB compared with average and an ALS phenotype (Table 1) . Functional studies by Niwa et al who tested 10 VCP mutations (R93C, R95G, R155C, R155H, R155P, R159H, R191Q, L198W, A232E, and N387H) found that all have increased ATPase activity over the wild type, with the A232E mutant having 3 times higher activity suggesting that mutations result in gain of VCP function. 18, 40 Interestingly the R159C mutation was associated with a later age of onset of myopathy compared with other molecular subtypes in our cohort of families. Additionally, PDB was absent in this large family, and also in two other reported families. 11, 41 PDB was seen only in one individual with this mutation in an ALS family 42 suggesting a protective effect of the R159C mutation from PDB. Among families of European ancestry, patients of German, 17, 43 Italian, 41, 44, 45 Spanish, 46 Austrian, 47 Belgian, 48 French, 49 Irish, 50 
| Global distribution and ethnic diversity of VCP mutations
